We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Urine Sediment Findings in Patients With COVID-19-Associated Renal Injuries

By LabMedica International staff writers
Posted on 11 Apr 2022
Print article
Image: The UC-3500 is a stand-alone fully automated urine chemistry analyzer (Photo courtesy of Advanced Medical & Diagnostics)
Image: The UC-3500 is a stand-alone fully automated urine chemistry analyzer (Photo courtesy of Advanced Medical & Diagnostics)

Patients with COVID-19 can suffer from renal complications, especially acute kidney injury (AKI). AKI is a frequent complication in patients with critically severe COVID-19, and a meta-analysis report has shown that the average incidence of AKI was 11% among all subjects with COVID-19 and 23% among critically ill patients.

Urinalysis and urine sediment examinations are the oldest and most commonly performed tests for assessing the pathophysiological condition of the kidney/urethral system. Urinalysis findings such as proteinuria, hematuria, and leukocyturia are reportedly associated with COVID-19-associated renal injuries and the severity of COVID-19.

Clinical Laboratory Scientists at the University of Tokyo Hospital (Tokyo, Japan) collected residual urine samples from 88 subjects with COVID-19 (total: 279 samples; average: three samples per patient; range: 1–16 samples) diagnosed using RT-PCR. The also collected urine samples from 78 subjects (total: 147 samples; average: two samples per patient; range: 1–9 samples) with acute renal injuries caused by non-COVID-19 factors, who were admitted to an emergency or intensive care unit (ICU).

The urine sediment examination was performed using manual microscopy. For the measurement of urinary clinical markers, the team used the following reagents: urinary creatinine (uCr) was measured using an enzyme assay (L-type Wako CRE • M; FUJIFILM Wako Pure Chemical, Osaka, Japan); total protein (TP) (Micro TP-test Wako) was measured using the pyrogallol red method; microalbumin (µAlb) (Auto Wako microalbumin; FUJIFILM Wako) was measured using a turbidimetric immunoassay (TIA); N-acetyl-β-D-glucosaminidase (Ltype Wako NAG) was measured using an enzyme assay; α1-MG (LZtest ‘Eiken’ α1-M; Eiken Chemical, Tokyo, Japan) was measured using latex agglutination turbidimetry;

Liver type fatty acid-binding protein (L-FABP) (NORUDIA L-FABP; SEKISUI MEDICAL, Japan) was measured using latex agglutination turbidimetry; and NGAL (U-NGAL Abbott; Abbott Park, IL, USA) was measured using a chemiluminescence immunoassay (CLIA). Urinary specific gravity (SG) was measured using an Eiken Chemical automated urine chemical analyzer US-3500 and urinary sodium was measured using an electrode method.

The investigators reported that that the number of urine sediment particles and the levels of N-acetyl-β-D-glucosaminidase, α1-microglobulin, liver type fatty acid-binding protein, and neutrophil gelatinase-associated lipocalin were associated with the severity of COVID-19. In addition, they observed that the number of granular casts, epithelial casts, waxy casts, and urinary chemical marker levels were lower in the subjects with COVID-19 than subjects without COVID-19 with acute renal injuries when the subjects were classified according to their renal function.

The authors concluded that the urinary sediment findings were milder in subjects with COVID-19 when compared according to their renal functions, suggesting that pre-renal injury factors might be largely involved in the pathogenesis of COVID-19-associated renal injuries than non-COVID-19-associated renal injuries in patients with AKI arising from surgery or sepsis. The study was published on April 1, 2022 in the International Journal of Infectious Diseases.

Related Links:
University of Tokyo Hospital
FUJIFILM Wako Pure Chemical
SEKISUI MEDICAL
Abbott
Eiken Chemical
 

Gold Supplier
Saliva Collection Kit
SpeciMAX Stabilized Saliva Collection Kit
New
Gold Supplier
Immunofluorescence Incubator
RaFIA Immunofluorescence Incubator
New
3-DIFF Hematology Analyzer
MYTHIC 18
New
Gold Supplier
Automatic Biochemistry Analyzer
Biossays C8

Print article

Channels

Molecular Diagnostics

view channel
Image: This image depicts a DNA molecule that is methylated on both strands on the center cytosine. DNA methylation plays an important role for epigenetic gene regulation in development and cancer (Photo courtesy of Wikimedia Commons)

Study Supports Use of Methylated DNA Biomarkers for Cancer Diagnosis and Prognosis

A recent study added weight to the theory that methylated DNA biomarkers could be used for cancer diagnosis and prognosis. Methylation is a biological process by which methyl groups are added to a DNA molecule.... Read more

Hematology

view channel
Image: Standard test for multiple myeloma provides clues of a rare, more deadly type (Photo courtesy of Pexels)

Standard Blood Cancer Test Provides Clues of Rare IgD Multiple Myeloma

IgD myeloma accounts for about 1% of common blood cancer multiple myeloma and has a worse prognosis. Specific testing for IgD myeloma is available at a handful of reference labs across the US, but takes... Read more

Industry

view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.